![](/img/cover-not-exists.png)
PCN144 IBRUTINIB TREATMENT IS ASSOCIATED WITH LOWER HEALTHCARE RESOURCE UTILIZATION AND TOTAL COST REDUCTION COMPARED TO CHEMOIMMUNOTHERAPY IN PATIENTS WITH MANTLE CELL LYMPHOMA
Iyengar, R., Malangone-Monaco, E., Sugg, C., Arthur, D., Sainski-Nguyen, A., Gelwicks, S., Giafis, N.Volume:
22
Journal:
Value in Health
DOI:
10.1016/j.jval.2019.04.268
Date:
May, 2019
File:
PDF, 324 KB
2019